<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01233739</url>
  </required_header>
  <id_info>
    <org_study_id>RIZACONDRO</org_study_id>
    <nct_id>NCT01233739</nct_id>
  </id_info>
  <brief_title>Chondroitin Sulphate Treatment Efficacy in Rhizarthrosis.</brief_title>
  <official_title>Chondroitin Sulphate Treatment Efficacy in Rhizarthrosis. Measurement With Sensory and Quantitive Functional Tests and Concordance Analysis With Subjective Scales of Pain.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Juan A. Arnaiz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who present rhizarthrosis diagnostic will be randomized to be treated with
      chondroitin sulfate or placebo during 24 weeks to study the effect of the treatment with
      objective and subjective indicators of pain and sensibility.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">April 2013</completion_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation with visual analogue pain scale as mean at the last weak</measure>
    <time_frame>36 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sollerman test</measure>
    <time_frame>36 weeks</time_frame>
    <description>Evaluation of hand function with Sollerman test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hand pressure force</measure>
    <time_frame>36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thumb-index finger pincer force</measure>
    <time_frame>36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dash test</measure>
    <time_frame>36 weeks</time_frame>
    <description>Osteoarthritis functional test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-12 test</measure>
    <time_frame>36 weeks</time_frame>
    <description>Quality of life test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical sensitivity measured with electronic Von Frey filament</measure>
    <time_frame>36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vibratory and thermic sensibility threshold assisted by computer</measure>
    <time_frame>36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of paracetamol or other analgesic drugs</measure>
    <time_frame>36 weeks</time_frame>
    <description>recorded in a patient diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of trapezium-thumb metacarpal joint by ultrasound scan</measure>
    <time_frame>36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematologic evaluation</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical evaluation</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Rhizarthrosis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Chondroitin sulfate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of 2 capsules of 400 mg of chondroitin sulfate orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chondroitin sulfate</intervention_name>
    <description>Administration of 2 capsules of 400 mg of chondroitin sulfate orally.</description>
    <arm_group_label>Chondroitin sulfate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administration of 2 capsules of placebo orally.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  both sex patients

          -  age between 45 to 75 years

          -  with mechanical pain at the trapezium-thumb metacarpal joint of more than 3 months
             duration

          -  grade II or III Eaton &amp; Glickel rhizarthrosis radiological diagnose

          -  pain at inclusion of &gt;= 40 mm at a visual analogue scale

          -  without rehabilitation treatment or infiltration in the last 6 months

          -  who accept to participate and sign informed consent

        Exclusion Criteria:

          -  patients with rhizarthrosis resulted from rheumatic disease

          -  patients with joint surgery or traumatic background

          -  illiterate patients or unable to understand informed consent

          -  patients with previous neuropsychopathology enough severe to unable participation at
             the study

          -  patients with peripheral sensory impairment due to diabetes, peripheral neuropathy or
             central neurological sequelae of disease in the affected limb that can alter sensory
             perception

          -  patients with coagulopathy

          -  inflammation for other process at the joint at study

          -  in treatment with non-steroidal anti-inflammatory drug in the last 7 days and/or
             corticosteroid in the last 30 days

          -  allergy or hypersensibility at chondroitin sulfate or its excipients

          -  pregnant or breastfeeding woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joaquím Forés, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínic i Provincial de Barcelona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Judit Pich, Pharmacist</last_name>
    <phone>+34 93 227 54 00</phone>
    <phone_ext>2336</phone_ext>
    <email>jpich@clinic.ub.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Clínic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08038</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Joaquim Forés, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2010</study_first_submitted>
  <study_first_submitted_qc>November 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2010</study_first_posted>
  <last_update_submitted>February 21, 2013</last_update_submitted>
  <last_update_submitted_qc>February 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Juan A. Arnaiz</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>rhizarthrosis</keyword>
  <keyword>Chondroitin sulfate</keyword>
  <keyword>Placebo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

